This study aimed to examine the kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease without diabetes. Participants were haphazardly allocated (1:1) to get placebo and afterward dapagliflozin 10 mg for every day or the other way around. Qualified members for this examination were grown-up patients (matured 18–75 years) with ongoing kidney sickness, without a finding of diabetes, with a 24-h urinary protein discharge more noteworthy than 500 mg and not exactly or equivalent to 3500 mg and an expected glomerular filtration rate (eGFR) of in any event 25 mL/min per 1·73 m 2, and who were on stable renin–angiotensin framework bar.
The essential result was rate change from pattern in 24-h proteinuria during dapagliflozin treatment comparative with fake treatment. Auxiliary results were changes in estimated GFR (mGFR; through iohexol leeway), bodyweight, circulatory strain, and groupings of neurohormonal biomarkers. Examinations were done as per the goal to-treat guideline.
The distinction in mean proteinuria change from benchmark among dapagliflozin and fake treatment was 0·9% (95% CI −16·6 to 22·1; p=0·93). Contrasted and fake treatment, mGFR was changed with dapagliflozin treatment by −6·6 mL/min per 1·73 m 2 (– 9·0 to −4·2; p<0·0001) at week 6. 6-week therapy with dapagliflozin didn’t influence proteinuria in patients with persistent kidney infection without diabetes, yet initiated an intense and reversible decrease in mGFR and a decrease in bodyweight.
To conclude,we can say that , Long-term clinical preliminaries are in progress to decide if SGLT2 inhibitors can securely diminish the pace of major clinical kidney results in patients with constant kidney infection with and without diabetes.
Ref: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30162-5/fulltext
